ARK Genomic Revolution ETF $ARKG Shares Sold by Prudential PLC

Prudential PLC reduced its holdings in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 24.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 136,470 shares of the company’s stock after selling 45,200 shares during the quarter. Prudential PLC owned 0.31% of ARK Genomic Revolution ETF worth $3,323,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. LPL Financial LLC lifted its stake in shares of ARK Genomic Revolution ETF by 13.4% during the first quarter. LPL Financial LLC now owns 783,702 shares of the company’s stock worth $16,270,000 after purchasing an additional 92,444 shares in the last quarter. Clearwater Capital Advisors LLC grew its stake in shares of ARK Genomic Revolution ETF by 24.0% in the first quarter. Clearwater Capital Advisors LLC now owns 195,875 shares of the company’s stock valued at $4,066,000 after buying an additional 37,970 shares in the last quarter. Raymond James Financial Inc. raised its holdings in shares of ARK Genomic Revolution ETF by 65.4% during the 1st quarter. Raymond James Financial Inc. now owns 142,362 shares of the company’s stock valued at $2,955,000 after buying an additional 56,283 shares during the period. Next Capital Management LLC acquired a new position in ARK Genomic Revolution ETF during the 2nd quarter worth approximately $318,000. Finally, Simplex Trading LLC acquired a new position in ARK Genomic Revolution ETF during the 2nd quarter worth approximately $936,000.

ARK Genomic Revolution ETF Stock Performance

BATS ARKG opened at $29.02 on Friday. ARK Genomic Revolution ETF has a fifty-two week low of $17.51 and a fifty-two week high of $31.16. The business has a 50 day moving average price of $29.19 and a two-hundred day moving average price of $25.72.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.